Skip to main content
Clinical Trials/NCT00948025
NCT00948025
Terminated
Not Applicable

A Multicenter, Prospective, Randomized, Comparative Study of Hollow Nerve Conduit and Avance Nerve Graft Evaluating Recovery Outcomes of Nerve Repair in the Hand. (CHANGE)

Axogen Corporation4 sites in 1 country23 target enrollmentJune 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Traumatic Nerve Injury
Sponsor
Axogen Corporation
Enrollment
23
Locations
4
Primary Endpoint
Recovery of Static 2-point Discrimination in the Affected Digit
Status
Terminated
Last Updated
5 years ago

Overview

Brief Summary

This study is a comparison of sensory recovery outcomes following the use of AVANCE Nerve Graft or hollow tube conduit for peripheral nerve gap repairs in the hand.

Detailed Description

The CHANGE study is a post-marketing study designed as a prospective, single-blind, randomized, two phase study comparing clinical outcomes of AVANCE Nerve Graft to hollow tube conduits. The first phase (pilot phase) assesses projected differences expected between two treatment groups. The second phase of the study provides comparison data between the two treatment groups. AVANCE Nerve Graft is current regulated in the United States as a 361 HCT/P Tissue for transplantation; not a Drug, Biologic, or Medical Device. Hollow tube conduits are currently regulated in the United States as medical devices.

Registry
clinicaltrials.gov
Start Date
June 2009
End Date
December 2014
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Require primary or secondary nerve injury repair with Hollow Nerve Conduit or AVANCE™ in at least 1 digital nerve;
  • Undergo End to End nerve to nerve graft coaptation on both the proximal and distal portion of the nerve gap in the AVANCE™ group or nerve entubulation in the Hollow Nerve Conduit group;
  • Be willing to comply with all aspects of the treatment and evaluation schedule over a 12 Month duration; and
  • Sign and date an IRB-approved written informed consent prior to initiation of any study procedures, including screening procedures.

Exclusion Criteria

  • Nerve gaps of \< 5 mm or \> 20 mm;
  • Estimated distance of regeneration of \>125 mm (distance from injury site to sensory target)
  • Nerve crush or avulsion injuries;
  • Incomplete nerve transections;
  • Injury requiring replantation of target digit;
  • Contralateral digital injuries corresponding to the target digit;
  • Nerve injuries in the affected limb proximal to the crease of the wrist;
  • End to side nerve repair;
  • Injuries with significant vascular damage which may impair adequate perfusion of the target limb;
  • Subjects who are undergoing treatment with chemotherapy, radiation therapy, or other know treatment which affects the growth of neural and/or vascular system;

Outcomes

Primary Outcomes

Recovery of Static 2-point Discrimination in the Affected Digit

Time Frame: 12 Months

Mean change in static 2-Point Discrimination between baseline and 12 months

Secondary Outcomes

  • Pain at 12-months(12-months)
  • Moving 2-point Discrimination(12 months)
  • Semmes-Weinstein Monofilament Assessment(12 months)
  • 12-month DASH Core Module Scores(12 months)
  • 12-month DASH (Work Module) Scores(12 month)
  • Thermal Discretion at 12-months(12-month)
  • 12- Month DASH (Sports/Performing Arts Module)(12 months)
  • Protective Sensation Present at 12-months(12 months)
  • Functional Recovery Classification (Medical Research Council Evaluation of Sensory Function) at 12-months(12 months)

Study Sites (4)

Loading locations...

Similar Trials